(Alliance News) - PureTech Health PLC on Tuesday said its affiliate, Vedanta Biosciences, has initiated a first-in-patient clinical study of its immuno-oncology candidate VE800.
The clinical stage biotechnology company said the study will focus on patients with select types of advanced or metastatic cancer and will evaluate the safety, tolerability and clinical activity of VE800.
Vedanta will target enrolment of over 100 patients in the US, diagnosed with advanced or metastatic melanoma, gastric/gastroesophageal junction adenocarcinoma or microsatellite-stable colorectal cancer, PureTech said. Topline results are anticipated in 2021.
"In preclinical work, VE800 was observed to enhance the ability of T-cells to infiltrate tumours, promoting suppression of tumour growth and suggesting enhanced survival. This is why we believe it has the potential to substantially improve outcomes for patients with advanced or metastatic cancers," said Bharatt Chowrira, president and chief of business and strategy at PureTech.
PureTech shares were trading 2.4% lower in London on Tuesday afternoon at 248.00 pence each.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
PureTech (PRTC)